{
    "name": "cysteine",
    "comment": "Rx",
    "other_names": [
        "Elcys",
        "Nouress"
    ],
    "classes": [
        "Nutritional",
        "Supplements"
    ],
    "source": "https://reference.medscape.com/drug/nouress-elycs-cysteine-1000356",
    "pregnancy": {
        "common": [
            "Appropriate administration is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Animal reproduction studies have not been conducted with cysteine"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data available on the effects of cysteine on infants, either directly or through breastmilk, do not suggest a significant risk of adverse events from exposure",
            "Although there are no data on the presence of cysteine in human or animal milk or the effects on milk production, appropriate administration is not expected to cause harm to a breastfed infant",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to one or more AAs",
                "Inborn errors of AA metabolism due to risk of severe metabolic or neurologic complications",
                "Pulmonary edema or acidosis due to low cardiac output"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress reported; in some fatal cases, pulmonary embolism occurred due to calcium precipitates; if signs of pulmonary distress occur, stop parenteral nutrition infusion, initiate a medical evaluation, and periodically inspect the solution and infusion set",
                "For admixture use only and must be diluted; it is not direct IV infusion; solutions with an osmolarity (>900 mOsm/L) infuse through a central catheter; infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis",
                "IV infusion of AAs may induce a rise in BUN, especially in patients with impaired hepatic or renal function; perform appropriate laboratory tests periodically and discontinue infusion if BUN levels exceed normal postprandial limits and continue to rise",
                "Administration may result in metabolic acidosis in preterm infants; administration of AA solutions to a patient with hepatic impairment may result in serum AA imbalances, metabolic alkalosis, prerenal azotemia, hyperammonemia, stupor, and coma; frequent clinical evaluation and laboratory determinations are necessary for proper monitoring of acid-base balance during parenteral nutrition",
                "Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive parenteral nutrition (eg, cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis, cirrhosis, possibly leading to hepatic failure); etiology of these disorders is thought to be multifactorial and may differ between patients; monitor liver function parameters and ammonia levels",
                "Hyperammonemia is of special significance in infants, as it can result in neurocognitive delays; closely monitor blood ammonia levels in infants; instances of asymptomatic hyperammonemia reported in patients without overt liver dysfunction",
                "Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment may be at higher risk of aluminum toxicity",
                "Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood cell count, and coagulation parameters throughout treatment"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Local infusion site reactions",
            "percent": null
        },
        {
            "name": "including a warm sensation",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "phlebitis",
            "percent": null
        },
        {
            "name": "and thrombosis",
            "percent": null
        },
        {
            "name": "at the infusion site",
            "percent": null
        },
        {
            "name": "Generalized flushing",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "and nausea",
            "percent": null
        }
    ]
}